• Co-Diagnostics amended its equity distribution agreement with Maxim, removing the fixed cap on aggregate sales of common stock.
• Future sales will be limited only by the amount of common stock registered and available under its effective shelf registration statement.
• Extended a no-issuance covenant with May 19, 2026 investors through 5:00 p.m. ET on Aug. 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-034837), on July 27, 2026, and is solely responsible for the information contained therein.